Melanotan I vs Melanotan II: Receptor Selectivity Comparison

The Melanocortin Receptor Family

The melanocortin receptor family comprises five G protein-coupled receptors: MC1R, MC2R, MC3R, MC4R, and MC5R. Each has distinct tissue distribution and physiological roles. MC1R is expressed primarily on melanocytes and drives eumelanin synthesis. MC2R is restricted to the adrenal cortex and responds to ACTH. MC3R and MC4R are central nervous system receptors involved in energy homeostasis, sexual behaviour, and inflammation modulation. MC5R is expressed in exocrine glands and immune cells. Melanotan I and Melanotan II are synthetic α-MSH analogues that differ substantially in which of these receptors they activate.

Melanotan I: MC1R-Selective

Melanotan I (also known as Afamelanotide or NDP-α-MSH) is a 13-amino-acid linear peptide structurally similar to α-melanocyte-stimulating hormone, with two strategic substitutions: D-Phe at position 7 and Nle at position 4. These modifications protect against proteolytic degradation and substantially increase MC1R binding affinity. Melanotan I shows strong selectivity for MC1R over the other melanocortin receptors, producing primarily melanogenic effects in research models without significant central nervous system or appetite-modulating activity.

Melanotan II: Broad Spectrum Melanocortin Agonism

Melanotan II is a cyclic heptapeptide α-MSH analogue with broader binding across the melanocortin receptor family. It activates MC1R (melanogenesis), MC3R and MC4R (central effects on appetite, energy expenditure, and sexual behaviour), and MC5R (exocrine function). The cyclic structure stabilises the peptide and increases potency, but it sacrifices the MC1R selectivity of Melanotan I. Research models using Melanotan II therefore show effects across multiple receptor systems simultaneously.

Why Selectivity Matters in Research

The receptor selectivity difference has direct experimental consequences. A researcher studying isolated MC1R-driven melanogenesis pathways will choose Melanotan I to avoid confounding from MC3R/MC4R/MC5R activation. A researcher examining central appetite regulation or sexual behaviour mediated through MC3R/MC4R will choose Melanotan II or a more selective MC4R agonist such as PT-141. The two compounds are not interchangeable in experimental design despite both being marketed under similar names.

Research Background

Both compounds were originally developed by the University of Arizona in the 1980s under principal investigators Hadley and Hruby, with the intent of developing melanocortin receptor research tools and potential clinical agents. Melanotan I (as Afamelanotide) has subsequently received clinical approval in some jurisdictions for the treatment of erythropoietic protoporphyria. Melanotan II has remained restricted to research applications. Neither compound is approved for human use in the UK by the MHRA.

Laboratory Handling

Both peptides are supplied as lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the side of the vial. Store reconstituted solutions at 2-8°C and use within 4 weeks. Protect from prolonged light exposure during handling.

Sourcing in the UK

Peptaro supplies research-grade Melanotan I 10mg and Melanotan II 10mg with the certificate of analysis for each batch published on the product page. Same-day UK dispatch on orders placed before 3pm UK time. For in-vitro laboratory research use only. Vial sizes and pricing are listed on the Melanotan 1 UK and Melanotan 2 UK buy pages.